Teachers Advisors LLC Cuts Position in Halozyme Therapeutics, Inc. (HALO)
Teachers Advisors LLC cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 73.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 190,502 shares of the biopharmaceutical company’s stock after selling 535,827 shares during the period. Teachers Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,469,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of HALO. Ameritas Investment Partners Inc. bought a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $122,000. Stifel Financial Corp bought a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $187,000. Karp Capital Management Corp bought a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $188,000. Parametrica Management Ltd bought a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $212,000. Finally, Highbridge Capital Management LLC bought a new position in shares of Halozyme Therapeutics during the fourth quarter worth approximately $215,000. Institutional investors own 81.09% of the company’s stock.
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded up 0.34% during trading on Wednesday, hitting $11.94. The stock had a trading volume of 45,445 shares. Halozyme Therapeutics, Inc. has a one year low of $8.18 and a one year high of $15.20. The stock’s 50-day moving average price is $12.96 and its 200 day moving average price is $13.14. The stock’s market cap is $1.60 billion.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million during the quarter, compared to analyst estimates of $31.76 million. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period last year, the company earned ($0.21) EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post ($0.97) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/16/teachers-advisors-llc-cuts-position-in-halozyme-therapeutics-inc-halo.html.
HALO has been the subject of a number of research reports. BidaskClub upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 16th. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Friday, August 11th. Piper Jaffray Companies set a $20.00 target price on Halozyme Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 10th. Canaccord Genuity set a $16.00 target price on Halozyme Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, ValuEngine upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $14.75.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.